Author(s):
Suyunov Nizom Davurovich, Rajabova Nargiza Khalimovna
Email(s):
Email ID Not Available
DOI:
10.52711/0974-360X.2026.00313 
Address:
Suyunov Nizom Davurovich1, Rajabova Nargiza Khalimovna2*
1Doctor of Sciences in Pharmaceutics, Professor, Head of Department of Pharmaceutical Organization of the Tashkent Pharmaceutical Institute, ORCID: 0000-0002-2712-958X
2Doctor of Philosophy (PhD) Pharmaceutical Sciences, Senior Lecturer of the Department of Pharmaceutical Organization of the Tashkent Pharmaceutical Institute. ORCID:0000-0003-2237-150X
*Corresponding Author
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, with adenocarcinoma and squamous cell carcinoma being the predominant histological subtypes. The high cost of novel therapies has led to the need for comprehensive pharmacoeconomic evaluations to optimize treatment strategies. This study was determined on the evaluation of the effectiveness of medicines used for in non-small cell lung cancer by intellectual analysis methods. A questionnaire was conducted among medical experts and the research used statistical, modern methods of intellectual data analysis, methods of processing information on medicines consumption, in particular preprocessing, domination intervals and generalized estimations. The results of the expert assessment serve as a basis for improving the supply of medicines to patients with lung cancer, and for the production of new medicines or their generics for manufacturing pharmaceutical enterprises. The results of the expert assessment serve as a basis for improving the supply of medicines to patients with lung cancer, and for the production of new medicines or their generics for manufacturing pharmaceutical enterprises.
Cite this article:
Suyunov Nizom Davurovich, Rajabova Nargiza Khalimovna. Methods of Intelligent Analysis for Assessing The Effectiveness of Medicines used in Non-Small Cell Lung Cancer. Research Journal Pharmacy and Technology. 2026;19(5):2171-8. doi: 10.52711/0974-360X.2026.00313
Cite(Electronic):
Suyunov Nizom Davurovich, Rajabova Nargiza Khalimovna. Methods of Intelligent Analysis for Assessing The Effectiveness of Medicines used in Non-Small Cell Lung Cancer. Research Journal Pharmacy and Technology. 2026;19(5):2171-8. doi: 10.52711/0974-360X.2026.00313 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-5-34
REFERENCES:
1. Borisova EI, Gutorov SL, Abramov ME. Tactics of treatment with erlotinib for non-small cell lung cancer: a literature review and clinical case descriptions. Meditsinsky Soviet. 2019; (19): 38–43. doi:10.21518/2079-701X-2019-19-38-43
2. Yukalchuk DY, Ponomarenko DM, Dvornichenko VV, Novopashin AM. Experience of durvalumab use in stage III unresectable non-small cell lung cancer in the Irkutsk region. Meditsinsky Alphabet. 2019; 3(28): 5–8. Available from: https://www.med-alphabet.com/jour/article/view/1193/1169
3. Artamonova EV. Vinorelbine in the treatment of non-small cell lung cancer. Meditsinsky Alphabet. 2021; (10): 8–15. Available from: https://www.med-alphabet.com/jour/article/view/2054/1893
4. Laktionov KK, Sarantseva KA, Breder VV, Okruzhnova MA, Peregudova MV. The role of immuno-oncology in the treatment of non-small cell lung cancer. Zlokachestvennye Opukholi. 2016; 3(19): 17–24. Available from: https://cyberleninka.ru/article/n/mesto-immunoonkologii-v-lechenii-nemelkokletochnogo-raka-legkogo/viewer
5. Moiseenko FV, Volkov NM, Abduloeva NX, Levchenko NV, Chubenko VA, Zhabina AS, et al. Outcomes of immunotherapeutic drugs in non-small cell lung cancer in real-world clinical practice. Zlokachestvennye Opukholi. 2020; 10(1): 5–20. Available from: https://cyberleninka.ru/article/n/rezultaty-primeneniya-immunoterapevticheskih-preparatov-pri-nemelkokletochnom-rake-legkogo-v-realnoy-klinicheskoy-praktike/viewer
6. Cao D, Chen D, Xia JN, Wang WY, Zhu GY, Chen LW, et al. Artesunate promotes anti-tumor immunity and overcomes EGFR-TKI resistance in non-small cell lung cancer by enhancing oncogenic TAZ degradation. Biomed Pharmacother. 2022; 155: 113705. doi:10.1016/j.biopha.2022.113705
7. Fukuda M, Kitazaki T, Ogawara D, Ichiki M, Mukae H, Maruyama R, et al. Randomized phase II study of pemetrexed alone or pemetrexed plus bevacizumab in elderly patients with previously untreated non-squamous non-small cell lung cancer: Results from the Lung Oncology Group in Kyushu (LOGIK1201). Lung Cancer. 2019; 132: 1–8. doi:10.1016/j.lungcan.2019.01.008
8. Succony L, Rassl DM, Barker AP, McCaughan FM, Rintoul RC. Adenocarcinoma spectrum lesions of the lung: detection, pathology, and treatment strategies. Cancer Treat Rev. 2021; 99: 102237. doi:10.1016/j.ctrv.2021.102237
9. Remon J, Pignataro D, Novello S, Passiglia F. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer. Cancer Treat Rev. 2021; 95: 102178. doi:10.1016/j.ctrv.2021.102178
10. Ranjan J. Application of data mining techniques in the pharmaceutical industry. J Theor Appl Inf Technol. 2007; 3: 61–7.
11. Madrakhimov SF, Rozikhodjaeva GA, Makharov KT. Construction of fuzzy inference rules for medical diagnostics problems. J Phys Conf Ser. 2021; 2032: 012032. doi:10.1088/1742-6596/2032/1/012032
12. Adane K, Muluye D, Abebe M. Processing medical data: a systematic review. Arch Public Health. 2013; 71: 27. doi:10.1186/0778-7367-71-27
13. Ignatev NA, Rahimova MA. Formation and analysis of informative feature sets of objects by class pairs. Sci Tech Inf Proc. 2022; 49: 439–45. doi:10.3103/S0147688222060053
14. Rocha A, Goldenstein SK. Multiclass from binary: expanding one-versus-all, one-versus-one and ECOC-based approaches. IEEE Trans Neural Netw Learn Syst. 2014; 25(2): 289–302. doi:10.1109/TNNLS.2013.2274735
15. Krivenko MP. Supervised classification of incomplete clinical data. Informatika i eyo primeneniya. 2017; 11(3): 27–33. doi:10.14357/19922264170303
16. Madrakhimov SF, Makharov KT, Khurramov AKh. Selection of informative features considering data gaps. Problems Comput Appl Math. 2023; 4(42): 147–57.
17. Suyunov ND. Pharmacoeconomic surveillance of pharmaceutical support for patients with chronic obstructive pulmonary disease in Uzbekistan. Pulmonologiya. 2011; 3: 64–9. doi:10.18093/0869-0189-2011-0-3-64-69
18. Shirokova IR. Cancer control: betting on innovations. MS. 2008; 7–8. Available from: https://cyberleninka.ru/article/n/borba-s-rakom-stavka-na-innovatsii
19. Maniadakis NM, Fragoulakis V, Pallis AG, Simou E, Georgoulias V. Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin as front-line treatment of advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis. Ann Oncol. 2010; 21(7): 1462–7. doi:10.1093/annonc/mdp551
20. Permsuwan U, Thongprasert S, Sirichanchuen B. Cost-utility analysis of first-line pemetrexed plus cisplatin in non-small cell lung cancer in Thailand. Value Health Reg Issues. 2020; 21: 9–16. doi:10.1016/j.vhri.2019.04.005
21. Ding H, Xin W, Tong Y, Sun J, Xu G, Ye Z, Rao Y. Cost-effectiveness of immune checkpoint inhibitors for non-small cell lung cancer: a systematic review. PLoS One. 2020; 15(9): e0238536. doi:10.1371/journal.pone.0238536
22. Pisareva LF, Odintsova IN, Ananina OA, Volkov MV, Gurina LI, Boyarkina AP. Epidemiology of lung cancer in Siberia and the Russian Far East. Pulmonologiya. 2013; (5): 5–8. doi:10.18093/0869-0189-2013-0-5-5-8
23. Andreev DA, Zavyalov AA. Organization of internal quality control of medical care for lung cancer patients: the Netherlands experience. Malignant Tumors. 2022; 12(1): 5–12. doi:10.18027/2224-5057-2022-12-1-5-12
24. Andreev DA, Zavyalov AA, Polyakova KI, Davydovskaya MV. Tyrosine kinase inhibitors in advanced lung cancer: experience from Moscow's preferential drug provision system. Pulmonology. 2020; 30(4): 463–72. doi:10.18093/0869-0189-2020-30-4-463-472
25. Xue C, Hu Z, Jiang W, Zhao Y, Xu F, Huang Y, et al. National survey on the medical treatment of non-small cell lung cancer (NSCLC) in China. Lung Cancer. 2012; 77(2): 371–5. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0169500212001821